NCT07910565
Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 4 words
- Secondary endpoints: details revised at 1 of 9 entries
- Study title expanded, about 8 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants with ESR1 mutations detected by reflex tissue NGS
Timeframe: From enrollment through study completion (up to 5 years)
Secondary (9)
Progression-free survival (PFS)
Rate of ESR1 mutation detection by liquid biopsy and ctDNA tumor fraction
Reflex Tissue NGS testing rate
Number participants initiating Selective Estrogen Receptor Degraders (SERD) therapy
Number participants SERD therapy by SERD agent
Show 4 moreShow less
Actionable genomic alterations detected by liquid biopsy and tissue NGS.
Other genomic alterations detected at disease progression
Correlation of HRR gene findings with variant origin and germline confirmation
Correlation of HER2 status with ERBB2 copy number
Arms and interventions
HR+/HER- metastatic breast cancer at diagnosis or experiencing disease progressionExperimental
Participants with ESR1 mutations in HR+/HER- metastatic breast cancer undergoing tissue biopsy for ctDNA Tumor Fraction (TF) testing using next-generation sequencing (NGS) after an indeterminate negative result in liquid biopsy (F1LCDx).
Diagnostic tests: FoundationOne® Liquid CDx (F1LCDx), Reflex tissue biopsy
Sites
1 site in 1 country
- Yale New Haven Hospital - Yale Cancer CenterNew Haven, Connecticut, United States